CRP and metabolic dysfunction-associated steatotic liver disease: The hypothesis that CRP affects NAFLD by affecting the insulin pathway was further substantiated in the mammalian target of rapamycin (mTOR), one of the downstream effectors of IGF-1 and AMPK.